Structure Therapeutics (GPCR) Cash from Investing Activities (2022 - 2026)
Quarterly Cash from Investing Activities fell 1560.19% to -$496.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$441.2 million through Mar 2026, down 35.21% year-over-year, with the annual reading at $89.8 million for FY2025, 125.02% up from the prior year.
Structure Therapeutics' Cash from Investing Activities history spans 5 years, with the latest figure at -$496.9 million for Q1 2026.
- Cash from Investing Activities came in at -$496.9 million for Q1 2026, down from $56.1 million in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $56.1 million in Q4 2025 to a low of -$496.9 million in Q1 2026.
- The 5-year median for Cash from Investing Activities is -$16.7 million (2022), against an average of -$64.5 million.
- Year-over-year, Cash from Investing Activities crashed 1847.84% in 2023 and then skyrocketed 2300.07% in 2025.
- Structure Therapeutics' Cash from Investing Activities stood at $10.3 million in 2022, then plummeted by 1847.84% to -$180.7 million in 2023, then surged by 118.39% to $33.2 million in 2024, then surged by 68.93% to $56.1 million in 2025, then crashed by 985.19% to -$496.9 million in 2026.
- Per Business Quant, the three most recent readings for GPCR's Cash from Investing Activities are -$496.9 million (Q1 2026), $56.1 million (Q4 2025), and -$49.3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | -2.89 Mn |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | 638.50 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | -431.90 Mn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | -428.90 Mn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | -25.54 Mn |
| 10 | Structure Therapeutics | 8.43 Bn | 8.43 Bn | - | -496.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -496.95 Mn |
| Mar 31, 2026 | -496.95 Mn |
| Dec 31, 2025 | 56.14 Mn |
| Dec 31, 2025 | 56.14 Mn |
| Sep 30, 2025 | -49.32 Mn |
| Sep 30, 2025 | -49.32 Mn |
| Jun 30, 2025 | 48.94 Mn |
| Jun 30, 2025 | 48.94 Mn |
| Mar 31, 2025 | 34.03 Mn |
| Mar 31, 2025 | 34.03 Mn |
| Dec 31, 2024 | 33.23 Mn |
| Dec 31, 2024 | 33.23 Mn |
| Sep 30, 2024 | -189.04 Mn |
| Sep 30, 2024 | -189.04 Mn |
| Jun 30, 2024 | -204.52 Mn |
| Jun 30, 2024 | -204.52 Mn |
| Mar 31, 2024 | 1.42 Mn |
| Mar 31, 2024 | 1.42 Mn |
| Dec 31, 2023 | -180.74 Mn |
| Dec 31, 2023 | -180.74 Mn |
| Sep 30, 2023 | 30.13 Mn |
| Sep 30, 2023 | 30.13 Mn |
| Jun 30, 2023 | -68.71 Mn |
| Jun 30, 2023 | -68.71 Mn |
| Mar 31, 2023 | -49.02 Mn |
| Mar 31, 2023 | -49.02 Mn |
| Dec 31, 2022 | 10.34 Mn |
| Dec 31, 2022 | 10.34 Mn |
| Sep 30, 2022 | -16.66 Mn |
| Sep 30, 2022 | -16.66 Mn |
| Jun 30, 2022 | -16.07 Mn |
| Jun 30, 2022 | -16.07 Mn |
| Mar 31, 2022 | -39.72 Mn |
| Mar 31, 2022 | -39.72 Mn |